Skip to main content
. 2021 Apr 29;12:664181. doi: 10.3389/fphar.2021.664181

FIGURE 6.

FIGURE 6

EMPA restored SNT-induced dysfunction of the AMPK–mTOR signaling pathway both in vitro and in vivo. (A) Western blots of the AMPK–mTOR pathway in H9c2 cardiomyocytes treated with different concentrations of SNT. (B) Protein-level quantifications of phosphorylated AMPK to total AMPK and phosphorylated mTOR to total mTOR ratios, n = 6 per group. (C) Western blots of the AMPK–mTOR pathway in H9c2 cardiomyocytes treated by vehicle, EMPA, SNT, or SNT plus EMPA. (D) Protein-level quantifications of phosphorylated AMPK to total AMPK and phosphorylated mTOR to total mTOR ratios, n = 6 per group. (E) Western blots of the AMPK–mTOR pathway in mice hearts treated by vehicle, EMPA, SNT, or SNT plus EMPA. (F) Protein-level quantifications of phosphorylated AMPK to total AMPK and phosphorylated mTOR to total mTOR ratios, n = 6 per group. *p < 0.05 vs. control, #p < 0.05 vs. SNT.